Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | WEE1 | P30291 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12671181 | 0.83 | ALK (0.42) | ALKBTKJAK3PTK2DGAT1 | |
| SCHEMBL13252757 | 0.83 | HTR2C (0.50) | ALKBTKJAK3PTK2DGAT1 | |
| SCHEMBL13252105 | 0.81 | PRKCQ (0.46) | ALKBTKJAK3PTK2DGAT1 | |
| SCHEMBL13252104 | 0.77 | MAP4K1 (0.63) | BRD4MAP4K1 | |
| SCHEMBL12671463 | 0.75 | MAP4K1 (0.51) | BRD4MAP4K1EGFR | |
| SCHEMBL13225903 | 0.72 | BRAF (0.41) | PTK2MAP3K5MAP4K1BRAF | |
| SCHEMBL13252759 | 0.70 | MAP4K1 (0.50) | BRD4MAP4K1 | |
| SCHEMBL13362919 | 0.68 | DGAT1 (0.41) | DGAT1MAP3K5MAP4K1BRAF | |
| SCHEMBL17915902 | 0.68 | SYK (0.49) | ALKBTKJAK3PTK2JAK2 | |
| SCHEMBL13252743 | 0.67 | DGAT1 (0.41) | DGAT1MAP3K5MAP4K1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | ALK 3665/4885BTK 2066/4885JAK3 2049/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | ALK 3321/4885BTK 2411/4885JAK3 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.